Accelerate Price To Sales Ratio from 2010 to 2024

AXDX Stock  USD 1.61  0.04  2.42%   
Accelerate Diagnostics Price To Sales Ratio yearly trend continues to be fairly stable with very little volatility. Price To Sales Ratio will likely drop to 3.85 in 2024. Price To Sales Ratio is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing Accelerate Diagnostics' market cap by its total sales or revenue over a 12-month period. View All Fundamentals
 
Price To Sales Ratio  
First Reported
2010-12-31
Previous Quarter
4.0558786
Current Value
3.85
Quarterly Volatility
3.7 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Accelerate Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Accelerate Diagnostics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.4 M, Interest Expense of 8.1 M or Selling General Administrative of 35.9 M, as well as many indicators such as Price To Sales Ratio of 3.85, Dividend Yield of 2.0E-4 or Days Sales Outstanding of 75.39. Accelerate financial statements analysis is a perfect complement when working with Accelerate Diagnostics Valuation or Volatility modules.
  
Check out the analysis of Accelerate Diagnostics Correlation against competitors.
For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.

Latest Accelerate Diagnostics' Price To Sales Ratio Growth Pattern

Below is the plot of the Price To Sales Ratio of Accelerate Diagnostics over the last few years. Price to Sales Ratio is figured by comparing Accelerate Diagnostics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Accelerate Diagnostics sales, a figure that is much harder to manipulate than other Accelerate Diagnostics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Accelerate Diagnostics' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Accelerate Diagnostics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 3.30 X10 Years Trend
Slightly volatile
   Price To Sales Ratio   
       Timeline  

Accelerate Price To Sales Ratio Regression Statistics

Arithmetic Mean2,504
Geometric Mean167.02
Coefficient Of Variation149.26
Mean Deviation3,232
Median110.53
Standard Deviation3,738
Sample Variance14M
Range9.5K
R-Value(0.53)
Mean Square Error10.8M
R-Squared0.28
Significance0.04
Slope(442.92)
Total Sum of Squares195.7M

Accelerate Price To Sales Ratio History

2024 3.85
2023 4.06
2022 4.57
2021 27.35
2020 38.03
2019 99.08
2018 110.53

About Accelerate Diagnostics Financial Statements

Accelerate Diagnostics investors use historical fundamental indicators, such as Accelerate Diagnostics' Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Accelerate Diagnostics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price To Sales Ratio 4.06  3.85 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Accelerate Stock Analysis

When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.